A股異動丨至純科技接近漲停 中國14nm芯片提前實現量產
格隆匯1月13日丨至純科技(603690.SH)接近漲停,報35.38元,總市值91.6億元。1月9日當天,我國芯片製造商中芯國際發來好消息,14納米級芯片已提前實現量產。據悉,2019年第三季度,中芯國際的芯片工廠第一代14納米FinFET工藝已成功量產,這也是我國首條14納米生產線。按照中芯國際的計劃,順利達產之下,中芯南方廠將建成兩條月產能均為3.5萬片的集成電路先進生產線。在中國半導體產業不斷取得突破之下,美國卻在擔憂自家芯片遭斷供。據某媒體2019年10月報道,美國有關部門代表人士鼓勵美國科技企業回國重建半導體生產線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.